MR elastography is highly repeatable and weakly correlates with age.
MR elastography-derived shear stiffness can be an objective biomarker of the intervertebral disc (IVD) degeneration process, according to a recent study. In a cross-sectional study, published in Radiology, in vivo lumbar MR elastography was performed once in the morning and once in the afternoon in 47 subjects without low back pain. Patients were ages 20 to 71 years. Researchers used principal frequency analysis to assess degeneration grade and MR elastography-derived sheer stiffness of the nucleus pulposus and annulus fibrous regions of all lumbar IVDs. According to results, there were no significant differences between morning and afternoon shear stiffness at all levels, and technical repeating between morning and afternoon imaging results for both nucleus pulposus (R=0.92) and annulus fibrous (R=0.83) regions were very good. Both experienced significant increases in MR elastography shear stiffness with increasing degeneration grade (nucleus pulposus grade 1, 12.5 kPa ± 1.3; grade 5, 16.5 kPa ± 2.1; annulus fibrosus grade 1, 90.4 kPa ± 9.3; grade 5, 120.1 kPa ± 15.4). There were weak correlations between shear stiffness and age at all levels. Overall, researchers wrote, MR elastography-derived shear stiffness measures were highly repeatable, correlated weakly with age, and increase with advancing IVD degeneration. This could suggest the stiffness may provide an objective biomarker of IVD degeneration processes.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.